Bioprocess Capital Ventures is a closed-end mutual fund of High-Risk (venture) investment. The fund was formed on December 19, 2007 engaging RVC and Vnesheconombank.
The investment activity of the fund is directed to stimulate the development of Biotechnology, Pharmacy, Fine Chemistry in Russia (in accordance with the priorities of the Russian Federation to transition the economy to one of innovative development).
Currently the fund's portfolio contains 6 companies from the Pharmacy and Biotechnology Areas, 2 companies from the Fine Chemistry Area and 1 Telecommunications Company. 6 of the fund's projects became Skolkovo's residents. Fund also had given grants for a total amount of nearly RUB 695 mln. (according to the data as of the end of the Third Quarter of 2014).
Name | Bioprocess Capital Ventures |
Form of Incorporation | Close-End Mutual Funds of High-Risk (Venture) Investments |
Trust Management Rules | Registration No. 0945-94131984 |
End Date of Formation | December 19, 2007 |
VAV as of the end of formation | RUB 3,000,000,000 |
Number of issued shares | 3,000 shares |
Share Owners |
RVC Vnesheconombank SC Fund's Venture Specialists |
Management Company | Bioprocess Capital Partners Management Company LLC |
The Investment Committee was formed by MC and consists of the representatives of each limited liability partner. Each of them is entitled to participate in the fund's management, act on behalf of the fund or vote on the issues pertaining to the fund, except the representatives of RVC, having a consultative vote.
Development of anti-cancer drugs on the basis of the brand new scientific concept of tissue specific
The development of a highly effective technology of medicinal drug production on the basis of curati
Production of electronic gases to a high purity degree, creation of substances for pharmaceuticals.
Development of original, therapeutic monoclonal antibody against autoimmune diseases and В-cell chr
Address: 6 Stolovy per., 121061, Moscow, Russia
+7 (495) 974-74-01,+7 (495) 974-74-02